Induction of endoplasmic reticulum stress and activation of the intrinsic apoptotic pathway is widely believed to contribute to β-cell death in type 1 diabetes (T1D). MCL-1 is an antiapoptotic member of the BCL-2 protein family, whose depletion causes apoptosis in rodent β-cells in vitro. Importantly, decreased MCL-1 expression was observed in islets from T1D
Secretion of pro-inflammatory cytokines by immune cells contributes to β-cell death in type 1 diabetes (T1D) (1) and exposure of human islets in vitro to the pro-inflammatory cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ) induce global changes in gene expression (2) that are remarkably similar to those observed in laser-captures islet cells from T1D patients (3) . One of the mechanisms involved in cytokine-mediated β-cell killing is the induction of endoplasmic reticulum (ER) stress and the consequent activation of the intrinsic (mitochondrial) apoptotic pathway (4; 5) . The intrinsic apoptotic pathway is regulated by the B-cell lymphoma 2 (BCL-2) family of proteins, which is divided into three groups: the anti-apoptotic members (e.g. MCL-1, BCL-2), the pro-apoptotic BH3-only proteins (e.g. BIM, DP5/HRK, PUMA) and the multi-BH (BCL-2 Homology) domain pro-apoptotic protein BAX and BAK (5; 6).
MCL-1 prevents apoptosis induced by BIM and PUMA, two BH3 only proteins that contribute to ER stress and inflammatory cytokine induced β-cell killing (5; 7-9). MCL-1 protein is expressed in rodent β-cells and cytotoxic insults that induce β-cell apoptosis, such as inflammatory cytokines, reduce MCL-1 protein expression in these cells (7; 10; 11) . Importantly, MCL-1 overexpression protects primary rat β-cells against diverse cytotoxic conditions (7; 11).
Moreover, overexpression of microRNA-29 (miR-29) promotes β-cell death by decreasing MCL-1 protein expression (10) . Interestingly, abnormally reduced expression of MCL-1 is present in islets from T1D patients infected with a diabetogenic enterovirus, suggesting that defects in MCL-1 expression play a role in the development of human diabetes (12) .
We have previously shown that MCL-1 protein expression is reduced in inflammatory cytokinetreated β-cells due to the combined actions of ER stress-mediated translation arrest and JNKinduced MCL-1 phosphorylation, which was reported to prime this protein for ubiquitination and proteasomal degradation (11) . Given the importance of MCL-1 in the survival of β-cells, the aim
RESEARCH DESIGN AND METHODS

Materials
The cytokine concentrations utilised were based on prior studies (13) (14) (15) and are described in Suppl. Table 1 . The GSK3α/β inhibitors SB216763 and BIO (Sigma-Aldrich, Diegem, Belgium)
were dissolved in DMSO (1:1000) and used at 5 µmol/L or 1 µmol/L, respectively. For immunoprecipitation experiments, cells were treated with the proteasome inhibitor MG-132 (Sigma-Aldrich, Diegem, Belgium) at 1 µmol/L.
Generation and characterisation of a β-cell specific Mcl-1 knockout mouse strain, islet isolation, culture and glucose-stimulated insulin secretion and cell lines utilized
The human β-cell line EndoCβH1 and the rat insulinoma cell line INS-1E were cultured as described (14) . Human islets were isolated from 6 non-diabetic organ donors (age 74±3 years; BMI 25±1 kg/m 2 , insulin positive cells 63±8%) in Pisa, Italy, with the approval of the local human research ethics committee. These islets were cultured and treated as described (16) .
Conditional Mcl-1 knockout mice were generated as described (17) were used as controls. βMcl-1KO mice were born at the expected normal Mendelian ratio. The non-fasted-glycaemia and body weight were followed in male and female βMcl-1KO mice and their respective WT littermates from 6-24 weeks (data not shown, and Suppl. Fig. 2 ). An intraperitoneal glucose tolerance test (ipGTT) was performed in these animals at 12 and 24 weeks of age. Mice were injected with 2g/kg body weight glucose after 6 h of fasting. At 24 weeks, mice were sacrificed and their pancreas collected for measuring the total pancreatic insulin content (19) or for immunofluorescence analysis (see below). Mice were housed and handled according to the Belgian Regulations for Animal Care and with permission from the local Ethic Committee.
For ex vivo experiments, mouse islets were isolated and cultured as described (20) . Glucosestimulated insulin secretion (GSIS) was performed in freshly isolated islets (19; 21). Insulin was quantified using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Downers Grove, USA). The GSIS experiments were performed and measured in triplicates.
Multiple low-dose streptozotocin treatment
Non-fasted male mice aged 7-8 weeks were injected i.p. for 5 consecutive days with either 42.5 mg/kg body weight streptozotocin (Sigma-Aldrich, Belgium) dissolved in citrate buffer (100 mM pH ≤ 4.5, made freshly) or citrate buffer alone. Blood glucose levels were measured on days -3, 1, 2, 3, 4, 5 pre-and post-injection and later weekly during 10 weeks after the last injection in non-fasting conditions using a glucometer (Accu-Chek, Roche, Switzerland) (22).
Hyperglycaemia was defined as non-fasting blood glucose levels >200 mg/dL in two sequential measurements. At the end of the experiment, the animals were sacrificed and the pancreas collected for histological analysis or for measuring the insulin content.
Immunofluorescence
Pancreatic tissues were collected and fixed overnight in 4% formaldehyde (BDH-Prolabo, Radnor, USA). Subsequently, the tissues were embedded in paraffin and at least 3 different sections were stained for analysis as described (23). Antibodies used are listed in Suppl. Table 2 .
Semi-quantitative analysis of insulin and glucagon staining was performed by analysing at least 3 different pancreas sections of 3 different animals per genotype, with a minimum of 15 islets examined per animal.
RNA interference, transient transfection, infection with recombinant adenovirus and sitedirected mutagenesis
The small interfering (si)RNAs (30 nmol/L) used are listed in Suppl. Table 3 and transfections were performed as described (13; 16; 24) . MCL-1 overexpression was achieved by transient transfection with a plasmid encoding rat MCL-1 (16) or by adenoviral infection (11) . Control adenoviruses encoding luciferase or β-galactosidase were obtained from SIRION Biotech (Martinsried, Germany). The expression vector for FLAG-tagged rat MCL-1 (Agilent Technologies, Santa Clara, USA) was kindly provided by Prof. Eminy Lee (Institute of Biomedical Science of Taipei, Taiwan). Sequences encoding non-tagged rat MCL-1 were cloned into the pExpress plasmid (Express Genomics, MD, USA). The constructs encoding the phosphorylation site mutants of rat MCL-1 were generated using the Q5-Site directed mutagenesis kit (NEB, Ipswich, USA) using the WT rat Flag-MCL-1 vector as a template.
Assessment of cell viability
The percentages of viable, apoptotic and necrotic cells were determined using the DNA-binding dyes Propidium Iodide (PI, 5 µg/mL, Sigma-Aldrich) and Hoechst 33342 (HO, 5 µg/mL, SigmaAldrich), as described (11) . In all experiments, the numbers of necrotic cells were low (between 1.8-2.1%) and did not change between the different conditions. For mouse islets, the percentages of dead cells were evaluated in a minimum of 10 islets per condition. All assessments were performed by two independent researchers one of whom was unaware of the identity of the samples.
Quantitative RT-PCR, immunoprecipitation and Western blot analysis
Poly(A) + mRNA was isolated and reverse-transcribed as described (16) . The real-time PCR amplification reaction was performed using SYBR Green and compared with a standard curve (25). All primers used are listed in Suppl. Table 3. For total cellular extracts, cells were lysed in Laemmli buffer and for immunoprecipitation 1x
RIPA buffer and the lysates were processed as described in (26). Western blot analysis was performed as described (11) . The antibodies used are listed in the Suppl. Table 2 . Images were acquired by Chemidoc (BioRad, Temse, Belgium) and analysed using ImageJ 1.49 software (27).
Flow cytometric analysis (FACS)
Single mouse islet cell preparations were obtained as described (20) . To exclude dead cells, cells
were stained using the LIVE/DEAD fixable dead cell stain kit (Life Technologies, Belgium).
APC-anti-human CD4 (mouse, clone RPA-T4) antibody was used to assess Mcl-1 gene deletion (28; 29). Cells were acquired on a FACSCanto II flow cytometer (BD Biosciences) and the data were analyzed using the FlowJo software (TreeStar, Ashland, OR) (29). The sorting of β-cell enriched cell populations was performed as described (30).
Statistical Analysis
Data are presented as means ± SEM. Comparisons were performed by two-tailed paired Student's t-test or by ANOVA followed by paired t-test with Bonferroni correction for multiple comparisons. A p value of <0.05 was considered as statistically significant.
RESULTS
Pro-inflammatory cytokines decrease MCL-1 protein expression in human pancreatic β-cells contributing to apoptosis.
Exposure of human EndoCβH1 cells to IL-1β+IFN-γ or TNF+IFN-γ for 16h induced significant increase in β-cell apoptosis that was further slightly increased at 24h (Suppl. 1a). By 24h, these inflammatory cytokines also caused a significant reduction of the expression of MCL-1 protein (up to 50%) in EndoCβH1 cells (Fig. 1a) . We next exposed EndoCβH1 cells to different 
MCL-1 depletion in vivo sensitises mouse islet cells to inflammatory cytokine-mediated death and renders mice more susceptible to diabetes
To explore the role of MCL-1 in islet cells in vivo, we generated a β-cell specific Mcl-1 knockout mouse strain (βMcl-1KO). The expression of MCL-1 protein in islets was significantly reduced in βMcl-1KO mice as determined by Western blot analysis (Fig. 2a) . In βMcl-1KO mice, a human CD4 reporter is subjugated to Mcl-1 promoter/enhancer elements as described in (17) .
Therefore, β-cells in which Mcl-1 fl has been deleted expressed the hCD4 protein that can be detected by FACS using fluorochrome-labeled anti-human-CD4 antibodies. We observed that 91.3±0.5% of the β-cell enriched population from βMcl-1KO mice expressed the hCD4 protein, while only 3.9±0.3% of the β-cell depleted population expressed this marker (Fig. 2b) . As expected, hCD4 expression was undetectable in β cells from WT mice (Fig. 2b) . We next evaluated whether βMcl-1KO mice are more susceptible to diabetes induced by MLDSTZ, a treatment that induces a combined toxic autoimmune form of diabetes in mice (31; 32). As expected, both WT and βMcl-1KO mice developed hyperglycemia 10 days after the last injection of streptozotocin (Fig. 3a) . The pancreatic insulin content was decreased by 60-90% in animals of both genotypes as compared to control buffer injected mice ( Fig. 3c-d) . Interestingly, MLDSTZ-induced hyperglycaemia was more severe in βMcl-1KO mice, with a 2-fold increase in the AUC calculated based on the glycaemic values as compared to WT littermates (Figs. 3a- b). In line with this, the insulin content of pancreata from βMcl-1KO mice was >50% lower than in WT mice after MLDSTZ treatment (Fig. 3c) . Analysis of the pancreatic sections of both βMcl-1KO and WT mice showed a clear decrease in the numbers of islets as well as insulin staining in the MLDSTZ treated animals of both genotypes compared to the vehicle injected mice (Fig. 3e) . Islets from the MLDSTZ treated βMcl-1KO mice displayed reduced insulin staining compared to their WT counterparts ( Fig. 3e and Suppl. Fig. 2k ). In line with these observations, an increased percentage of α-cells was observed in MLDSTZ treated mice as compared to their vehicle treated counterparts ( Fig. 3e and Suppl. Fig. 2l ). Collectively, these results demonstrate that β-cells from βMcl-1KO mice are abnormally sensitive to stress.
GSK3β is critical for cytokine-mediated MCL-1 degradation
We have previously shown that the cytokine-mediated MCL-1 protein decrease in rat β-cells is a post-transcriptional process since these cells actually displayed increased Mcl-1 mRNA levels (11) . We have now made similar observations in human β-cells, since cytokines cause an increase in MCL-1 mRNA expression in EndoCβH1 cells (Suppl. Fig. 3a) . Studies in other cell types showed that MCL-1 protein stability can be regulated through phosphorylation by GSK3β, which primes MCL-1 for ubiquitination and proteasomal degradation (33). Inhibition of GSK3 using specific compounds did not affect MCL-1 protein expression under basal condition but it diminished the cytokine-mediated reduction in MCL-1 protein expression (Fig. 4a) . β-catenin, a known target of GSK3 kinase, was reported to be modulated by the GSK3 inhibitors. Inhibition of GSK3β activity induced a significant protection from cytokine-induced cell death in both rat
INS-1E cells and human EndoCβH1 cells (Figs. 4b-c).
GSK3β-targeted phosphorylation sites are conserved between human and rat MCL-1 ( Fig. 5a) (33). We therefore generated expression vectors for rat phosphorylation site mutant MCL-1 proteins in which serine 139 or 142, or threonine 143 were substituted for by the phospho-null residue alanine. Treatment with cytokines downregulated the levels of both the overexpressed and exogenous WT MCL-1 protein with similar kinetics as the endogenous MCL-1 protein in INS-1E cells (Suppl. Fig. 3b ). The expression levels of all MCL-1 protein forms were comparable in untreated cells (Suppl. Fig. 3c ). The T143A mutation diminished cytokinemediated decrease in MCL-1 protein expression at 16h but not at 24h (Fig. 5b) . Conversely, the S139A mutation resulted in more substantial protection against IL-1β+IFN-γ-induced MCL-1 degradation ( Fig. 5c ). Finally, the S142A mutation did not affect MCL-1 protein turnover ( 
DISCUSSION
MCL-1 is an anti-apoptotic member of the BCL-2 protein family that protects pancreatic cells against apoptosis by sequestering the multi-BH domain pro-apoptotic BAX/BAK proteins, and the pro-apoptotic BH3-only proteins, such as BIM and PUMA (7; 33). We have previously shown that a variety of cytotoxic stimuli, such as, pro-inflammatory cytokines, the ER stressor thapsigargin, the saturated acid palmitate and the viral mimetic double-stranded RNA, promote apoptosis by decreasing MCL-1 protein levels in rat β-cells (7; 11). We observed here that inflammatory cytokines also decrease MCL-1 protein expression in human β-cells and that this contributes to the apoptosis of these cells. Interestingly, dose response experiments indicated that relatively low levels of cytokines were already able to decrease MCL-1 levels and induce death of EndoCβH1 cells. These results are in line with a recent report, revealing decreased expression of MCL-1 in islets from T1D patients infected with diabetogenic enterovirus (12) . Collectively, these findings suggest that decreased levels of MCL-1 in β-cells may contribute to the development of diabetes.
We report here that MCL-1 overexpression partially protects human β-cell against the proapoptotic effect of pro-inflammatory cytokines. To evaluate the protective role of MCL-1 in immune-mediated β-cell death in vivo, we developed a β-cell specific Mcl-1 KO mouse strain.
βMcl-1KO mice were born at the expected Mendelian frequency and showed no obvious metabolic abnormalities even in adulthood. This is remarkable, because loss of MCL-1 in other essential cell types, such as neurons, cardiomyocytes or haematopoietic stem/progenitor cells, causes death of mice (36) (37) (38) (39) . It is therefore possible that during development β-cells are less dependent on MCL-1 than these other cell types, suggesting that the survival of β-cells may be safeguarded by other pro-survival BCL-2 family members (e.g. BCL-XL) or that several of these pro-survival proteins function in these cells in an overlapping manner.
In agreement with findings from Mcl-1 gene knockdown studies in rodent and human β-cells ((11) and present data), islets from the βMcl-1KO mice were abnormally susceptible to cell death induced by both IL-1β+IFN-γ or TNF+IFN-γ treatment. MLDSTZ treatment induces a slow and progressive decrease in insulin levels due to direct toxicity and islet inflammation with consequent β-cell killing (31; 32). The development of diabetes in our experiments followed the usual time course in this model, with hyperglycaemia appearing 10 days after the end of streptozotocin treatment, indicating that the disease was mainly due to islet inflammation.
Interestingly, MLDSTZ treatment induced a more pronounced hyperglycaemia in the βMcl-1KO mice compared to their WT littermates, as reflected by a 2-fold increase in the AUC calculated based on the glycaemic levels. In line with these data, there was a >50% decrease in insulin content in βMcl-1KO mice as compared to their WT littermates. Moreover, histological analysis of the pancreas showed a reduced percentage of insulin positive cells and an increased percentage of glucagon positive cells in the βMcl-1KO islets. The increased glucagon staining probably reflects the stronger depletion of insulin positive cells in the KO islets. These results indicate that MLDSTZ treatment causes increased β-cell destruction in the βMcl-1KO mice. This could be due to increased mononuclear cell infiltration in βMcl-1KO mice, since islets from these mice are probably more susceptible to STZ-and immune-induced cell death than wild type islets, and this could lead to increased inflammation (40) . Overall, our results establish the crucial role for MCL-1 in protecting mouse as well as human β-cells from apoptosis in vitro and during diabetes development in mice in vivo.
Our next aim was to unravel the regulatory mechanisms that drive inflammatory cytokine mediated MCL-1 downregulation in pancreatic β-cells. Due to its short half-life (~30 min; compared to ~20 h for BCL-XL and BCL-2), MCL-1 is disproportionally susceptible to alterations in protein translation (33). MCL-1 is structurally unique among other anti-apoptotic proteins of the BCL-2 family, since it contains an N-terminal domain with several phosphodegron motives that are associated with its rapid turnover (33; 34). JNK-mediated phosphorylation decreases MCL-1 protein stability, a process that can be prevented by JNK inhibitors (11) . Phosphorylation by GSK3β can also promote MCL-1 protein degradation, at least in cancer cells (33). We have now found that inhibition of GSK3β, using two specific compounds, diminishes IL-1β+IFN-γ mediated MCL-1 protein degradation. This was accompanied by a significant protection against cytokine-induced apoptosis in both rat and, importantly, human β-cells.
We hypothesised that mutations of the GSK-3β-targeted phospho-degrons might disrupt MCL-1 phosphorylation and thereby increase MCL-1 protein stability. In rat MCL-1, threonine 143 (corresponding to Thr163 in human MCL-1) acts as a critical primary phosphorylation site that then primes MCL-1 for subsequent phosphorylation at other sites, as shown in different cell types (41; 42) . Surprisingly, in our studies the T143A mutation only delayed cytokine mediated MCL-1 degradation. This suggests that phosphorylation of T143 contributes, but is not an absolute prerequisite for GSK3β-mediated phosphorylation of other sites in MCL-1 and its degradation in INS-1E cells (33; 34). This indicates that cell type specific differences exist in the post-translational modifications of MCL-1 and the control of its turnover. Furthermore, our studies revealed that serine 139 in rat MCL-1 (corresponding to S159 in human MCL-1) is critical for MCL-1 degradation in INS-1E cells. Indeed, the S159A mutation substantially FBW7 expression is downregulated after exposure to IL-1β+IFN-γ (Fig. 7) . In HeLa cells MULE was shown to ubiquitinate MCL-1 and thereby prime it for proteasomal degradation whereas, conversely, knockdown of MULE was found to increase MCL-1 protein levels in sarcoma cells and thereby protected them from apoptosis induced by DNA damage (34). In A293T cells, overexpression of βTrCP induced MCL-1 ubiquitination, followed by a decrease in its levels.
The opposite was seen when βTrCP expression was silenced (34). In agreement with these reports, we observed that knockdown of both MULE and βTrCP increased the levels of MCL-1 protein even when the INS-1E cells were exposed to IL-1β+IFN-γ. This suggests that proinflammatory cytokine-induced MCL-1 degradation depends on ubiquitination mediated by these inhibitor of apoptosis in β-cells (Fig. 7) .
In conclusion, the data presented here provide evidence that MCL-1 exerts a critical antiapoptotic role in human β-cells in vitro, and its deficiency affects diabetes development in mice.
Moreover, we clarified the mechanisms that regulate MCL-1 protein turnover in rat β-cells when exposed to a pro-inflammatory milieu (Fig. 7) . 
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